Date:\_09/27/23\_\_\_

Your Name: Patrick Bou-Samra

Royalties or licenses

Consulting fees

X\_None

\_X\_\_None

	Wanuscript Title: Cathepsin Detection To Identify Malignant Cells During Robotic Pulmonary Resection Wanuscript number (if known):_ TLCR-23-370				
rela part to t	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the sound of the manuscript. If you are in doubt about whether to list a so.		
	following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the current		
to t	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.				
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.					
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as			
		needed)			
		Time frame: Since the initial	al planning of the work		
1	All support for the present	_XNone			
	manuscript (e.g., funding,				
	provision of study materials, medical writing, article				
	processing charges, etc.)				
	No time limit for this item.				
			+		
		Time frame: pas	st 36 months		
2	Grants or contracts from	_X_None			
	any entity (if not indicated				
	in item #1 ahove)				

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
	•		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical	_	
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
Plea	se summarize the above co	nflict of interest in the fo	llowing box:

Date:_09/27/23	
Your Name: Austin Chang	
Manuscript Title: Cathepsin Detection To Identify Malignant Cells During Robotic Pulmonary Resect	ion
Manuscript number (if known):_ TLCR-23-370	
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below the	

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	_XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	No time limit for this item.		
		Time - former - 1 - 2 - 4	36 mantha
2	Grants or contracts from	Time frame: past	36 months
2	any entity (if not indicated	_X_None	
	in item #1 above).		
3	Royalties or licenses	_X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
	•		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical	_	
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
Plea	se summarize the above co	nflict of interest in the fo	llowing box:

Date:_09/27/23
Your Name: Emily Guo
Manuscript Title: Cathepsin Detection To Identify Malignant Cells During Robotic Pulmonary Resection
Manuscript number (if known):_ TLCR-23-370

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	_XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	No time illine for time item.		
		Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
	•		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical	_	
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
Plea	se summarize the above co	nflict of interest in the fo	llowing box:

Date:\_09/27/23\_

Royalties or licenses

Consulting fees

\_X\_None

\_X\_\_None

You	Your Name: Feredun Azari				
	Manuscript Title: Cathepsin Detection To Identify Malignant Cells During Robotic Pulmonary Resection Manuscript number (if known):_ TLCR-23-370				
rela part to ti	ted to the content of your miles whose interests may be	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.		
	The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .				
to tl	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.				
	em #1 below, report all sup time frame for disclosure is	·	in this manuscript without time limit. For all other items,		
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as			
		needed)			
		Time frame: Since the initia	l planning of the work		
1	All support for the present	_XNone			
	manuscript (e.g., funding,				
	provision of study materials,				
	medical writing, article processing charges, etc.)				
	No time limit for this item.				
	anne mine for tins itelli.				
		Time frame: past	36 months		
2	Grants or contracts from	X None	. So months		
_	any entity (if not indicated				
	in item #1 above).				

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
	•		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical	_	
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
Plea	se summarize the above co	nflict of interest in the fo	llowing box:

Date:\_09/27/23\_\_

Royalties or licenses

Consulting fees

X\_None

\_X\_\_None

You	r Name: Gregory Kennedy				
	Manuscript Title: Cathepsin Detection To Identify Malignant Cells During Robotic Pulmonary Resection Manuscript number (if known):_ TLCR-23-370				
rela part to t	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.		
	following questions apply t nuscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>		
to t	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.				
	em #1 below, report all sup time frame for disclosure is		I in this manuscript without time limit. For all other items,		
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as			
		needed)			
		Time frame: Since the initia	n planning of the work		
1	All support for the present	_XNone			
	manuscript (e.g., funding, provision of study materials,				
	medical writing, article				
	processing charges, etc.)				
	No time limit for this item.				
		Time frame: past	t 36 months		
2	Grants or contracts from	_X_None			
	any entity (if not indicated				
	in item #1 above).				

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
	•		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical	_	
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
Plea	se summarize the above co	nflict of interest in the fo	llowing box:

Date:September 27, 2023
Your Name:John T. Santini, Jr., PhD
Manuscript Title: Cathepsin Detection To Identify Malignant Cells During Robotic Pulmonary Resection
Manuscript number (if known): TLCR-23-370

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Vergent Bioscience	John receives salary and stock options as a full-time employee of the company.  The company also provided study drug (VGT-309) and funding for the clinical trial at the University of Pennsylvania where the data in the manuscript were generated.
		National Cancer Institute of the National Intitutes of Health	Vergent Bioscience is the awardee of SBIR grant R44CA277890, which supports the clinical trial at the University of Pennsylvania where the data in the manuscript were generated.

	Time frame: past 36 months				
2	Grants or contracts from				
	any entity (if not indicated				
	in item #1 above).				
3	Royalties or licenses	None			
4	Consulting fees	None			
5	Payment or honoraria for	None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
6	educational events	Nana			
6	Payment for expert testimony	None			
	testimony				
7	Support for attending	Vergent Bioscience	As an employee of the company, Vergent pays expenses		
′	meetings and/or travel	vergent bioscience	for John to travel to and attend scientific meetings.		
	meetings and/or traver		Tor some to traver to and attend scientific meetings.		
8	Patents planned, issued or pending	Vergent Bioscience	John is an inventor on a pending patent application		
			owned by Vergent.		
9	Participation on a Data	None			
9	Safety Monitoring Board or	INOTIE			
	Advisory Board				
10	Leadership or fiduciary role	None			
10	in other board, society,	None			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	Vergent Bioscience	As an employee of the company, John has stock options		
	·		in the company.		
12	Receipt of equipment,	None			
	materials, drugs, medical				
	writing, gifts or other				
4.5	services				
13	Other financial or non-	Vergent Bioscience	John is an executive of the company and receives a		
	financial interests		salary as a full-time employee.		

## Please summarize the above conflict of interest in the following box:

John receives salary and stock options as a full-time employee of the company.

The company also provided study drug (VGT-309) and funding for the clinical trial at the University of Pennsylvania where the data in the manuscript were generated.

Vergent Bioscience is the awardee of SBIR grant R44CA277890, which supports the clinical trial at the University of Pennsylvania where the data in the manuscript were generated.

As an employee of the company, Vergent pays expenses for John to travel to and attend scientific meetings.

John is an inventor on a pending patent application owned by Vergent.

As an employee of the company, John has stock options in the company.

John is an executive of the company and receives a salary as a full-time employee.

Please place an "X" next to the following statement to indicate your agreement:

**Date:** September 28, 2023 **Your Name:** Eric S. Bensen

Manuscript Title: Cathepsin Detection to Identify Malignant Cells During Robotic Pulmonary Resection

Manuscript number (if known): TLCR-23-370

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

1	All support for the present	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial Vergent Bioscience	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work  Eric receives salary and stock options as a full-time
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		employee of the company. The company also provided study drug (VGT-309) and funding for the clinical trial at the University of Pennsylvania where the data in the manuscript were generated.
		Time frame: past	
2	Grants or contracts from any entity (if not indicated in item #1 above).	National Cancer Institute of the National Institutes of Health	Vergent Bioscience is the awardee of SBIR grant R44CA277890, which supports the clinical trial at the University of Pennsylvania where the data in the manuscript were generated.
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or		
	educational events	News	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	Vergent Biosicence	As an employee of the company, Vergent pays expenses
,	meetings and/or travel	vergent biosicence	for Eric to travel to and attend scientific meetings.
	meetings and, or traver		Tot Elle to date to and attend scientific incestings.
8	Patents planned, issued or	Vergent Bioscience	Eric is an inventor on a pending patent application
"	pending	Vergent bioscience	owned by Vergent
	penam <sub>B</sub>		owned by vergent
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Vergent Bioscience	As an employee of the company, Eric has stock options
			in the company.
12	Receipt of equipment,	None	
12	materials, drugs, medical	INOTIC	
	writing, gifts or other		
	services		
13	Other financial or non-	Vergent Bioscience	Eric is a full-time employee of the company and receives
	financial interests		a salary and benefits from the company.

## Please summarize the above conflict of interest in the following box:

Eric receives salary and stock options as a full-time employee of the company.

The company also provided study drug (VGT-309) and funding for the clinical trial at the University of Pennsylvania where the data in the manuscript were generated.

Vergent Bioscience is the awardee of SBIR grant R44CA277890, which supports the clinical trial at the University of Pennsylvania where the data in the manuscript were generated.

As an employee of the company, Vergent pays expenses for Eric to travel to and attend scientific meetings.

Eric is an inventor on a pending patent application owned by Vergent

As an employee of the company, Eric has stock options in the company.

Eric is a full-time employee of the company and receives a salary and benefits from the company.

Date:\_09/27/23\_

Your Name: Dorraid Jarrar

Manuscript Title: Cathepsin Detection To Identify Malignant Cells During Robotic Pulmonary Resection Manuscript number (if known):_ TLCR-23-370				
rela part to t	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.			
	following questions apply to uscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>	
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.				
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
		Name all entities with	Specifications/Comments	
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your	
		none (add rows as	institution)	
		needed)		
		Time frame: Since the initial	planning of the work	
1	All support for the present	_XNone		
	manuscript (e.g., funding, provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: past	26	

\_X\_None

\_X\_None

\_X\_\_None

Grants or contracts from any entity (if not indicated

in item #1 above).

Royalties or licenses

Consulting fees

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
	•		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	X None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
Plea	se summarize the above co	nflict of interest in the fo	llowing box:

Date:_09/27/23
Your Name: Sunil Singhal
Manuscript Title: Cathepsin Detection To Identify Malignant Cells During Robotic Pulmonary Resection
Manuscript number (if known):_ TLCR-23-370
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that ar

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	_XNone	
	processing charges, etc.)  No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	XNone	
l			I .

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
	•		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	X None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
Plea	se summarize the above co	nflict of interest in the fo	llowing box: